Respiratory · 38 CFR 4.97 · Diagnostic Code 6819
Lung Cancer VA Disability Rating
TL;DR. Lung cancer rates 100% during active disease + at least 6 months after treatment ends (DC 6819). The mandatory 6-month exam transitions to residuals (PFT-based under DC 6604) if no recurrence. Dual presumptions: PACT Act for post-9/11 burn-pit exposure (added 2022) and Agent Orange for Vietnam-era veterans (long-standing under 38 CFR 3.309(e)). Most post-treatment residuals rate 30-100% based on FEV1/FVC/DLCO. Lung cancer is one of the most-claimed PACT Act presumptive cancers and one of the highest-leverage claims for qualifying veterans — no nexus opinion needed.
What lung cancer means in VA disability terms
Lung cancer for VA rating purposes is a primary malignant neoplasm of the lung — small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC: adenocarcinoma, squamous cell carcinoma, large cell carcinoma), and rarer histologies. Diagnosis is established by tissue biopsy or cytology. Metastatic disease from another primary site (e.g., colon cancer with lung metastases) does NOT rate under DC 6819; it rates under the primary cancer's code.
Full DC 6819 criteria
| Rating | Criteria |
|---|---|
| 100% | Neoplasm, malignant, any specified part of respiratory system, exclusive of skin growths. Rate active disease and for at least 6 months following the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. Following the 6-month period, a mandatory VA examination is conducted; if no local recurrence or metastasis, rating is based on residuals. |
The note to DC 6819 directs raters to evaluate residuals as a chronic respiratory condition under the appropriate code — usually DC 6604 (chronic bronchitis / COPD) or DC 6845 (interstitial lung disease), based on the functional pattern of impairment.
The 6-month residuals transition
The mandatory exam at 6 months post-treatment determines the transition:
- Recurrence or metastasis present: 100% continues.
- No recurrence: Rating reduced to residuals based on PFT findings. The reduction requires VA Notice procedures with a 60-day response window.
"Treatment ended" date varies by modality. Surgery: date of resection. Radiation: last day of course. Chemotherapy: completion of last cycle. Immunotherapy (durvalumab, pembrolizumab) given on continuous regimens: maintains 100% as long as treatment continues. Active surveillance after low-risk Stage IA resection: treatment is considered ended at resection date.
Post-treatment residuals (rate under PFT-based codes)
The residuals rating uses PFTs and follows the bracket pattern of chronic respiratory disease:
| Rating | PFT Criteria (DC 6604 chronic bronchitis pattern) |
|---|---|
| 10% | FEV1 of 71 to 80 percent predicted; OR FEV1/FVC of 71 to 80 percent; OR DLCO of 66 to 80 percent predicted. |
| 30% | FEV1 of 56 to 70 percent predicted; OR FEV1/FVC of 56 to 70 percent; OR DLCO of 56 to 65 percent predicted. |
| 60% | FEV1 of 40 to 55 percent predicted; OR FEV1/FVC of 40 to 55 percent; OR DLCO of 40 to 55 percent predicted; OR maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit). |
| 100% | FEV1 less than 40 percent predicted; OR FEV1/FVC less than 40 percent; OR DLCO less than 40 percent predicted; OR maximum oxygen consumption less than 15 ml/kg/min; OR cor pulmonale; OR requires outpatient oxygen therapy. |
Lung surgery (lobectomy, pneumonectomy) commonly produces lasting PFT impairment that supports 30-60% residuals even with no recurrence.
Service-connection paths
PACT Act presumption (post-9/11)
The PACT Act of 2022 added several lung cancers and respiratory conditions to the burn-pit presumptive list under 38 CFR 3.320 for qualifying post-9/11 veterans. The geographic scope is broad: Afghanistan (Sept 19, 2001 onward), Iraq, Kuwait, Saudi Arabia, the broader Southwest Asia theater, Syria, Djibouti, Egypt, Jordan, Lebanon, Yemen, Uzbekistan, Somalia, and other listed locations.
Agent Orange presumption (Vietnam-era)
Respiratory cancers including lung cancer have been on the Agent Orange presumptive list under 38 CFR 3.309(e) since 1994. Same qualifying service categories as for hypertension and diabetes: in-country Vietnam, Korean DMZ 1968-1971, Thailand base, Blue Water Navy (2019 BWNVAA), C-123 aircrew (2015).
Check PACT Act / Agent Orange eligibility →Radiation-exposure presumption
Atomic veterans (radiation-exposed during specified nuclear weapons testing or Hiroshima/Nagasaki occupation) have lung cancer on their presumptive list under 38 CFR 3.309(d).
Asbestos exposure (direct service connection)
Asbestos-related lung cancers (often with mesothelioma) require direct evidence of in-service asbestos exposure (typically Navy / shipyard veterans). Asbestos is not formally presumptive but the VA recognizes the link with proper exposure documentation.
Evidence the VA looks for
- For PACT Act: DD-214 with qualifying post-9/11 deployment locations and dates.
- For Agent Orange: DD-214 with qualifying Vietnam-era service.
- Biopsy / pathology report. Confirms diagnosis, histology, stage.
- Treatment record. Dates of surgery, radiation course, chemotherapy cycles, immunotherapy.
- Imaging. CT, PET-CT for staging and surveillance.
- Post-treatment PFTs. FEV1, FVC, DLCO — document residuals for the post-100% rating.
- Pulmonology and oncology notes. Specialist documentation carries substantial weight.
Common rating pitfalls
- Premature reduction at 6 months. If treatment continues (immunotherapy, hormone therapy for hormonally-driven cancers), the 100% continues. Appeal premature reductions.
- Missing PFTs at the 6-month exam. The residuals rating depends on PFT data. Ensure PFTs are done before or during the exam.
- Filing without presumption. Qualifying veterans should always file under PACT Act or Agent Orange presumption first.
- Stopping after the schedular reduction. Post-treatment residuals often qualify for 30-60% based on PFTs. Don't accept a 0% residual without challenging the PFT findings.
- Not claiming surgical scars or chemotherapy complications. Each may rate separately under its own code.
Worked example
Veteran: Army, deployed Iraq 2005-2006 and Afghanistan 2010-2011. Diagnosed adenocarcinoma of right upper lobe 2024, lobectomy + adjuvant chemotherapy 2024. PFT at 6-month exam: FEV1 65% predicted, DLCO 55%. No recurrence. Spouse + 2 children.
- Active period (during treatment + 6 months): 100% under DC 6819.
- At 6-month exam: no recurrence; transition to residuals.
- Residuals under DC 6604: worst-of (FEV1 65% = 30%, DLCO 55% = 60%). Rating: 60%.
- Service connection: PACT Act burn-pit presumption.
- 2026 monthly compensation (veteran + spouse + 2 children, 60%): $1,547.93/mo.
During the active 100% period: ~$4,500/mo. After residuals reduction: $1,547/mo at 60%. The DLCO is the dispositive PFT input — document it.
Common secondary conditions
- Surgical scars (DC 7800-7806). Thoracotomy / VATS scars when painful or unstable rate separately.
- Peripheral neuropathy from chemotherapy. Platinum agents cause peripheral neuropathy; rate per affected nerve under DC 8520-8730.
- Cardiotoxicity from chemotherapy or radiation. Anthracycline-induced cardiomyopathy, radiation-induced pericarditis. Rate under cardiac codes.
- Depression secondary to cancer diagnosis. Recognized secondary mental-health pathway.
- Secondary cancers from radiation. Long-latency radiation-induced cancers (typically ≥10 years post-treatment).
Sources cited in this article
- 38 CFR 4.97 — The Respiratory System (DC 6819, 6604)
- 38 CFR 3.320 — Toxic exposure presumptive (PACT Act)
- 38 CFR 3.309 — Presumptive service connection lists
- PACT Act of 2022 (H.R. 3967)
VetDisabilityCalc is an independent reference site operated by Zoom Lifestyle LLC. We are not VA-accredited and we do not prepare or present VA claims.